Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
0.2482
-0.0104 (-4.02%)
At close: Aug 1, 2025, 4:00 PM
0.2470
-0.0012 (-0.48%)
After-hours: Aug 1, 2025, 7:18 PM EDT

Company Description

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting.

It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.

In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings.

The company was incorporated in 2013 and is based in Salt Lake City, Utah.

Co-Diagnostics, Inc.
Co-Diagnostics logo
CountryUnited States
Founded2013
IPO DateJul 12, 2017
IndustryMedical Devices
SectorHealthcare
Employees132
CEODwight Egan

Contact Details

Address:
2401 S. Foothill Dr., Suite D
Salt Lake City, Utah 84109
United States
Phone(801) 438-1036
Websiteco-dx.com

Stock Details

Ticker SymbolCODX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001692415
CUSIP Number189763105
ISIN NumberUS1897631057
Employer ID46-2609396
SIC Code3841

Key Executives

NamePosition
Dwight H. EganChairman and Chief Executive Officer
Richard David AbbottPresident
Brian L. Brown CPAChief Financial Officer and Company Secretary
David NielsenChief Operating Officer
Dan Bohrer CPAVice President of Finance and Accounting
Christopher ThurstonChief Technology Officer
Andrew BensonHead of Investor Relations
Dr. Mayuranki Almaula Ph.D.Senior Vice President of Overseas Operations and Strategic Alliances
Seth EganChief Commercialization Officer

Latest SEC Filings

DateTypeTitle
Jul 11, 20258-KCurrent Report
May 29, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 28, 20258-KCurrent Report
Apr 14, 2025DEF 14AOther definitive proxy statements
Mar 27, 202510-KAnnual Report
Mar 27, 20258-KCurrent Report
Feb 21, 20258-KCurrent Report
Jan 10, 20258-KCurrent Report